Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

Discover ITM and its cancer candidate ITM-11 as it brings one of the first big wins the radiopharmaceutical sector awaits.

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

Effect of marital status and race on survival of patients with well differentiated neuroendocrine tumors (NETs). Clinicopathological factors related to survival in gastroenteropancreatic ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors. Among patients with unresectable or recurrent ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...